文献速递药物不良反应与药物警戒

司库奇尤单抗毒性信号:基于FAERS的药物警戒研究

Toxicity signals associated with secukinumab: A pharmacovigilance study based on the United States Food and Drug Administration Adverse Event Reporting System database.
PubMed 文献 · Br J Clin Pharmacol · 2022-10-07

本研究利用FAERS数据库2015至2021年数据,采用比例失衡分析(IC与ROR)探索司库奇尤单抗的四类主要毒性。共纳入73 945 398条记录,其中300 665条与司库奇尤单抗相关。炎症性肠病、生殖器念珠菌病、银屑病样皮炎和嗅觉丧失具有最高的IC025值,四类毒性发病时间主要集中在第一个月。

要点

  • 炎症性肠病IC025/ROR025为3.25/9.69,生殖器念珠菌病为3.46/11.54
  • 银屑病样皮炎IC025/ROR025为1.94/4.04,嗅觉丧失为1.62/3.17
  • 四类主要毒性的发病时间主要集中在用药后第一个月内

核心结论

  • 司库奇尤单抗存在需关注的高风险毒性信号,包括炎症性肠病、生殖器念珠菌病、银屑病样皮炎和嗅觉丧失。

研究设计与样本

  • 基于美国FDA不良事件报告系统(FAERS)2015至2021年数据的药物警戒研究,采用比例失衡分析。
  • 共纳入73 945 398条记录,其中300 665条与司库奇尤单抗相关。
  • 采用信息成分(IC)和报告比值比(ROR)两种方法检测信号,信号定义为ROR025 > 1且IC025 > 0。

主要发现

  • 最常见不良事件为腹泻(N = 3538)、鼻咽炎(N = 3458)、瘙痒(N = 4277)和皮疹(N = 3270)。
  • 炎症性肠病IC025/ROR025 = 3.25/9.69,生殖器念珠菌病IC025/ROR025 = 3.46/11.54。
  • 银屑病样皮炎IC025/ROR025 = 1.94/4.04,嗅觉丧失IC025/ROR025 = 1.62/3.17。
  • 四类主要毒性的发病时间主要集中在第一个月。
  • 部分患者同时出现两种或以上毒性。

临床怎么用

  • 用药后第一个月应重点监测腹泻、鼻咽炎、瘙痒、皮疹及上述高风险信号相关表现。
  • 对出现炎症性肠病、生殖器念珠菌病、银屑病样皮炎或嗅觉丧失的患者应及时评估与司库奇尤单抗的关联。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: Secukinumab, the first interleukin 17A inhibitor, is widely used to treat immune diseases, including plaque psoriasis, psoriatic arthritis and ankylosing spondylitis. Recently, many studies have reported adverse events associated with secukinumab, including gastrointestinal disorders, infections and infestations, and hypersensitive and nervous system disorders. OBJECTIVE: Here, we aimed to explore the clinical characteristics, outcomes and time to onset of the four main toxicities of secukinumab using post-marketing data. METHODS: Our study utilized data from the United States Food and Drug Administration Adverse Event Reporting System (FAERS) database from 2015 to 2021, using disproportionality analysis. Toxicities were defined based on the standardized Medical Dictionary for Regulatory Activities queries. Two disproportionality methods were used to detect potential signals: information component (IC) and reporting odds ratio (ROR). The signals were defined as ROR025 > 1 and IC025 > 0. RESULTS: A total of 73 945 398 records were included in this study, of which 300 665 records were related to secukinumab. Diarrhoea (N = 3538), nasopharyngitis (N = 3458), pruritus (N = 4277) and rash (N = 3270) were the most common adverse events. Inflammatory bowel disease (IC025 /ROR025 = 3.25/9.69), genital candidiasis (IC025 /ROR025 = 3.46/11.54), dermatitis psoriasiform (IC025 /ROR025 = 1.94/4.04) and anosmia (IC025 /ROR025 = 1.62/3.17) had the highest IC025 values of all toxicities. The time to onset of the four toxicities was mainly concentrated in the first month. Some patients simultaneously presented with two or more toxicities. CONCLUSION: This pharmacovigilance study systematically explored the four main toxicities of secukinumab and provided new safety signals based on past safety information. Some high-risk signals need to be given attention.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Zheng Y, Guo X, Chen C, et al. Toxicity signals associated with secukinumab: A pharmacovigilance study based on the United States Food and Drug Administration Adverse Event Reporting System database. Br J Clin Pharmacol. 2022. PMID: 36106653. doi:10.1111/bcp.15535

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。